1. Clinical utility of complement-dependent C3d assay in kidney recipients presenting with late allograft dysfunction
- Author
-
Lan, James H, Gjertson, David, Zheng, Ying, Clark, Stephanie, Investigators, DeKAF, Reed, Elaine F, and Cecka, Michael J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Kidney Disease ,Organ Transplantation ,Prevention ,Transplantation ,Adult ,Biological Assay ,Complement C3d ,Cross-Sectional Studies ,Female ,Follow-Up Studies ,Graft Rejection ,Graft Survival ,HLA Antigens ,Histocompatibility Testing ,Humans ,Isoantibodies ,Kidney Failure ,Chronic ,Kidney Transplantation ,Male ,Postoperative Complications ,Prognosis ,Prospective Studies ,Risk Factors ,Tissue Donors ,alloantibody ,antibody-mediated ,clinical research/practice ,histocompatibility ,kidney transplantation/nephrology ,rejection ,DeKAF Investigators ,Medical and Health Sciences ,Surgery ,Clinical sciences ,Immunology - Abstract
The objective of this study was to evaluate the utility of a complement-dependent C3d assay to risk stratify donor-specific antibodies (DSA) in a multicenter cohort of kidney recipients presenting with new-onset clinical dysfunction. A total of 106 subjects with evidence of DSA at a mean period of 5.3 ± 5.0 years posttransplant underwent testing using C3d reagents. C3d positivity was strongly associated with both the peak and sum IgG DSA MFI, with 98.3% (n = 57/58) of strongly reactive sera (peak MFI > 10 000) eliciting a positive signal. Patients with C3d+ DSA had a higher creatinine (P = .03), more significant graft fibrosis (P = .035), and a faster rate of graft loss posttest compared to those with C3d- DSA (P = .05). Subanalysis of patients with low-moderate level DSA confirmed the inferior outcome associated with C3d positivity. Despite the prognostic value of C3d as a stand-alone test, the assay did not provide independent risk prediction after incorporation of graft fibrosis in a multivariate model (P = .94). Overall, C3d offered limited discriminatory value for strong DSA with peak IgG MFI > 10 000 and in patients where histologic data is available, but its utilization may be considered in those with low-moderate level DSA and where an allograft biopsy is not accessible.
- Published
- 2018